Gaithersburg, MD, United States of America

Sujata Vijh

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignee: Macrogenics, Inc.. Active years: 2008-2015.

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 71.4

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 4.6

ph-index = 7

Forward Citations = 520(Granted Patents)

Company Filing History:

7 out of 132

Macrogenics, Inc.

patents

Years Active: 2008-2015

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9028815 - Identification and engineering of antibodies with variant FC regions and methods of using same (2015-05-12),

2. 8951517 - Identification and engineering of antibodies with variant Fc regions and methods of using same (2015-02-10),

3. 8445645 - Identification and engineering of antibodies with variant Fc regions and methods of using same (2013-05-21),

4. 8192737 - Identification and engineering of antibodies with variant Fc regions and methods of using same (2012-06-05),

5. 8003774 - Identification and engineering of antibodies with variant Fc regions and methods of using same (2011-08-23),

6. 7960512 - Identification and engineering of antibodies with variant Fc regions and methods of using same (2011-06-14),

7. 7355008 - Identification and engineering of antibodies with variant Fc regions and methods of using same (2008-04-08),

Title: Sujata Vijh: Innovator in Antibody Engineering

Introduction

Sujata Vijh is a prominent inventor based in Gaithersburg, MD (US). She has made significant contributions to the field of immunology, particularly in the engineering of antibodies. With a total of 7 patents to her name, her work focuses on enhancing the efficacy of therapeutic antibodies.

Latest Patents

One of her latest patents involves the identification and engineering of antibodies with variant Fc regions. This invention relates to molecules, specifically polypeptides, that comprise a variant Fc region. The variant Fc region includes at least one amino acid modification compared to a wild-type Fc region. This modification allows the variant Fc region to bind to FcγRIIIA and/or FcγRIIA with greater affinity than a comparable molecule with the wild-type Fc region. The molecules developed through this invention are particularly useful in preventing, treating, or ameliorating symptoms associated with various diseases, disorders, or infections. They are especially beneficial for conditions where enhanced efficacy of effector cell function, such as antibody-dependent cellular cytotoxicity (ADCC), is desired, including cancer and infectious diseases.

Career Highlights

Sujata Vijh is currently employed at Macrogenics, Inc., where she continues to advance her research in antibody engineering. Her innovative work has positioned her as a key figure in the development of therapeutic antibodies.

Collaborations

She collaborates with notable colleagues, including Jeffrey B. Stavenhagen and Christopher Rankin, contributing to a dynamic research environment.

Conclusion

Sujata Vijh's contributions to antibody engineering have the potential to significantly impact the treatment of various diseases. Her innovative patents and collaborative efforts highlight her role as a leading inventor in the field.